Loading...

TCRT ALAUNOS THERAPEUTICS INC Expansion Plans 8-K Filing

LNS

TCRT

ALAUNOS THERAPEUTICS INC

(TCRT)

2026 8-K

Positive Drug Data

Termination Notice

Settlement Agreement

Compliance Regained

Increase in authorized shares

Departures and Appointments

Equity Offerings

Equity Offerings

Equity Offerings

Director Resignation

Board Compensation

License Termination

Reverse Stock Split

Reverse Stock Split

Reverse Stock Split

Reverse Stock Split

Dismissal of Independent Re...

Annual Meeting Approval

Management Changes

Compliance regained with Na...

Reverse Stock Split

Reverse Stock Split

Appointment of Interim CEO

Appointment of Director and...

Management Changes

Resignation of Director

Management Departure

Financial Condition and Del...

Resignation and Appointment

Financial Results and Strat...

Voluntary Delisting

Annual Meeting Approval

Financial Results Announcement

License Agreement Amendment

Loan Agreement Amendment

Management Changes

Earnings Reports

Presentation and Press Release

External Links:

On March 2, 2026, Alaunos Therapeutics, Inc. announced positive preclinical results for their obesity drug candidate, ALN1003, from two studies. This filing reflects significant progress in their research efforts.

AI Assistant

ALAUNOS THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.